

### IN THE COMPETITION APPEAL TRIBUNAL

Case Nos: 1432/1/12/22

1434/1/12/22

1438/1/12/22 1439/1/12/22

### BETWEEN:

# (1) ADVANZ PHARMA CORP. LIMITED & OTHERS (2) CINVEN CAPITAL MANAGEMENT (V) GENERAL PARTNER LIMITED & OTHERS

## (3) LEXON (UK) LIMITED & ANOTHER (4) ALLIANCE PHARMACEUTICALS LIMITED & ANOTHER

**Appellants** 

- v -

### **COMPETITION AND MARKETS AUTHORITY**

Respondent

#### **ORDER**

**UPON** the application by the Respondent made on 7 April 2022 for directions from the Tribunal for (1) a consolidated Defence to be filed in relation to all appeals against the decision of the Respondent of 3 February 2022 in Case 50511-2 *Prochlorperazine* ("the Decision"), and (2) an extension of time for filing the consolidated Defence until 20 June 2022 ("the Application")

AND UPON READING the correspondence from the parties with respect to the Application

**AND HAVING REGARD TO** rules 15(1) and 19 of the Competition Appeal Tribunal Rules 2015

### IT IS ORDERED THAT:

1. The Respondent shall file a single consolidated Defence in respect of all appeals brought against the Decision.

2.	The time for the Respondent to file a single consolidated Defence is extended to 20
	June 2022.

3. Liberty to apply.

**Sir Marcus Smith**President of the Competition Appeal Tribunal

Made: 26 April 2022 Drawn: 26 April 2022